Brokerages Set AstraZeneca PLC (LON:AZN) Target Price at £104.12

Shares of AstraZeneca PLC (LON:AZN) have received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is £104.12 ($131.47).

Several research firms have issued reports on AZN. Berenberg Bank restated a “buy” rating and issued a £150 ($189.39) price objective on shares of AstraZeneca in a research note on Monday, September 2nd. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a £140 ($176.77) target price on shares of AstraZeneca in a report on Friday, November 22nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £110 ($138.89) target price on shares of AstraZeneca in a report on Tuesday, September 3rd.

Insider Buying and Selling at AstraZeneca

In other AstraZeneca news, insider Tony Mok purchased 1,500 shares of the stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average cost of £126.80 ($160.10) per share, for a total transaction of £190,200 ($240,151.52). Also, insider Pascal Soriot purchased 20,000 shares of the stock in a transaction dated Thursday, November 14th. The stock was acquired at an average price of £102.03 ($128.83) per share, for a total transaction of £2,040,600 ($2,576,515.15). 0.04% of the stock is currently owned by corporate insiders.

AstraZeneca Stock Performance

LON AZN opened at £105.56 ($133.28) on Wednesday. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. AstraZeneca has a 1 year low of GBX 9,461 ($119.46) and a 1 year high of £133.88 ($169.04). The company has a market capitalization of £163.62 billion, a PE ratio of 3,323.17, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a fifty day moving average of £109.74 and a two-hundred day moving average of £119.05.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.